Monoclonal antibody LYM-2
Alternative Names: LYM-2Latest Information Update: 11 Jan 2018
At a glance
- Originator Peregrine Pharmaceuticals
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 05 Jan 2018 Peregrine Pharmaceuticals is now called Avid Bioservices
- 07 Apr 2003 No development reported - Preclinical for Cancer in USA (unspecified route)
- 27 Nov 2000 Techniclone Corporation is now called Peregrine Pharmaceuticals